$131.45
1.07% yesterday
Nasdaq, Jun 27, 10:04 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$131.45
+2.92 2.27% 1M
+70.43 115.42% 6M
+69.10 110.83% YTD
-16.37 11.07% 1Y
+99.30 308.86% 3Y
+114.20 662.03% 5Y
+115.45 721.56% 10Y
+115.45 721.56% 20Y
Nasdaq, Closing price Fri, Jun 27 2025
+1.39 1.07%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Basic
Market capitalization
$4.4b
Enterprise Value
$4.6b
Net debt
$200.0m
Cash
$310.1m
Shares outstanding
33.8m
Valuation (TTM | estimate)
P/E
107.75 | 71.34
P/S
9.11 | 7.51
EV/Sales
9.52 | 7.85
EV/FCF
negative
P/B
16.70
Financial Health
Equity Ratio
28.43%
Return on Equity
15.51%
ROCE
6.72%
ROIC
9.98%
Debt/Equity
1.92
Financials (TTM | estimate)
Revenue
$488.2m | $592.0m
EBITDA
$52.8m | $117.4m
EBIT
$52.5m
Net Income
$49.0m | $62.3m
Free Cash Flow
$-63.2m
Growth (TTM | estimate)
Revenue
64.43% | 34.07%
EBITDA
473.81% | 211.46%
EBIT
469.17%
Net Income
580.37% | 75.80%
Free Cash Flow
68.84%
Margin (TTM | estimate)
Gross
59.47%
EBITDA
10.82% | 19.84%
EBIT
10.76%
Net
10.03% | 10.53%
Free Cash Flow
-12.95%
More
EPS
$1.22
FCF per Share
$-1.87
Short interest
40.14%
Employees
728.00
Rev per Employee
$610.00k
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a TransMedics Group, Inc. forecast:

12x Buy
75%
4x Hold
25%

Analyst Opinions

16 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
75%
Hold
25%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
488 488
64% 64%
100%
- Direct Costs 198 198
77% 77%
41%
290 290
57% 57%
59%
- Selling and Administrative Expenses 176 176
37% 37%
36%
- Research and Development Expense 62 62
10% 10%
13%
53 53
474% 474%
11%
- Depreciation and Amortization 0.30 0.30
200% 200%
0%
EBIT (Operating Income) EBIT 53 53
469% 469%
11%
Net Profit 49 49
580% 580%
10%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Positive
Seeking Alpha
5 days ago
TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beat...
Neutral
Schaeffers Research
16 days ago
With the way negative stock market sentiment  has piled up recently, short squeezes have generated some massive returns.
Positive
MarketBeat
16 days ago
In May, three stocks that released earnings stood out due to their massive sales beats. These names are mid-cap companies with market capitalizations between $2 billion and $10 billion.
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today